TCF-001 TRACK (Target Rare Cancer Knowledge) Trial
400
about 5.3 years
18+
1 site in MA
What this study is about
This trial is testing whether patients with rare tumors can benefit from matched molecular therapy based on their next-generation sequencing (NGS) results. It involves using FoundationOne CDx and FoundationOne Liquid CDx tests to help guide treatment decisions for adults diagnosed with cancer of unknown primary site, liver cancer, or other rare cancers.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.FoundationOne CDx and FoundationOne Liquid CDx
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Progression-free survival (PFS) among participants who received the molecularly targeted matched treatment.
Secondary: Comparison of Tumor Biomarker Profiling to Treatment Outcome.
Oncology